Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000678 | 0.98 | HRH3 (0.56) | POLBHRH3ALDH1A1HDAC1MITF | |
| SCHEMBL15104570 | 0.97 | POLB (0.50) | POLBHRH3ALDH1A1HDAC1MITF | |
| SCHEMBL374844 | 0.86 | KDM4E (0.51) | POLBHRH3ALDH1A1HDAC1MITF | |
| SCHEMBL374926 | 0.86 | PARP1 (0.43) | POLBHRH3KDM4E | |
| SCHEMBL23124848 | 0.80 | KCNH2 (0.45) | POLBHRH3ALDH1A1HDAC1KCNH2 | |
| SCHEMBL375294 | 0.78 | KDM1A (0.37) | POLBALDH1A1TSHRKDM4E | |
| SCHEMBL20605102 | 0.76 | HRH3 (0.51) | POLBHRH3ALDH1A1HDAC1TSHR | |
| SCHEMBL375612 | 0.76 | HTT (0.62) | POLBALDH1A1TSHRKDM4EPKM | |
| SCHEMBL2645047 | 0.75 | HRH3 (0.69) | POLBHRH3ALDH1A1HDAC1KCNH2 | |
| SCHEMBL11431895 | 0.75 | HRH3 (0.69) | POLBHRH3ALDH1A1HDAC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454240-A1 | GLYCINE TRANSPORTER INHIBITORS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL C0., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| WO-2011007899-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011007899-A1 | GLYCINE TRANSPORTER INHIBITORS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116095-A1 | GLYCINE TRANSPORTER INHIBITORS | SLC6A5, SLC1A2, SLC18A2 | POLB 3106/4885HRH3 452/4885ALDH1A1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.